510(k) Report

510(k) · Cleared

Cleared

Cedia Digoxin

K970881510(k) TraditionalCleared May 14, 199765-day reviewClass II21 CFR 862.3320

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Boehringer Mannheim Corp. · KXT Enzyme Immunoassay, Digoxin

Cleared on May 14, 1997 as substantially equivalent to K882233 (Abbott Laboratories, 1988) after a 65-day review. Its family tree reaches back 1 generation to 1988.

Decided
May 14, 1997
Review
65 days
Class
Class II
Product code
KXT
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to K882233 (1988). No later device cites it as a predicate yet.

K882233 · TDX (R) Digoxin NXT · Abbott Laboratories · 19881986198819901992199419961998
K882233 · TDX (R) Digoxin NXT · Abbott Laboratories · 19880
  1. Root · 1 generation backK882233 TDX (R) Digoxin NXTAbbott Laboratories · 1988
  2. This deviceK970881 Cedia DigoxinBoehringer Mannheim Corp. · 1997
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1K882233TDX (R) Digoxin NXTAbbott Laboratories1988—
0 (this device)K970881Cedia DigoxinBoehringer Mannheim Corp.1997—
FIG. 1 — Lineage of K970881, 1988–1997Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in KXT? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new KXT device

  1. #1 K193397 ADVIA Centaur® Digoxin assayscore 1.7 · 1 generation · no Class I recall
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K882233TDX (R) Digoxin NXT
Summary page 1
…products in commercial distribution intended for similar use. Most device notably it is substantially equivalent to the currently marketed Abbott TDx® Digoxin IT Assay (K882233). Continued on next page ~ page 28 510(k) Summary, Continued e BOEHRINGER MANNHEIM CORPORATION Device Descript…
Abbott Laboratories1988—

Also cleared against K882233: 6 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has no recall.
  • 6 other devices also cite its predicate K882233.

How does its category compare?

All KXT devices

KXT Enzyme Immunoassay, Digoxin: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · KXT

1in 2021

2008: 12010: 12011: 12016: 12021: 1
2007high 1 (2008) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · KXT

Too few KXT 510(k)s in any year since 2007 to give a median.

Recalls per year · KXT

1in 2008

2007: 32008: 1
2007high 3 (2007) · low 0 (2009)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · KXT

7in 2024

2007: 3102008: 62009: 92010: 112011: 192012: 152013: 392014: 72015: 12016: 42017: 192018: 12020: 52021: 12022: 32023: 42024: 7
2007high 310 (2007) · low 0 (2019)2025

MAUDE reports naming product code KXT, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—3310
20081—16
20090—09
20101—011
20111—019
20120—015
20130—039
20140—07
20150—01
20161—04
20170—019
20180—01
20190—00
20200—05
20211—01
20220—03
20230—04
20240—07
20250—00
20260—0—

What is it indicated for?

Immunoassay for the in vitro quantitative determination of Digoxin in serum and plasma.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K970881: Cedia Digoxin.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K970881

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026